PharmaCyte Biotech Inc (OTCMKTS:PMCBD – Get Free Report)’s share price fell 5.3% during mid-day trading on Thursday . The stock traded as low as $1.23 and last traded at $1.25. 18,546 shares traded hands during mid-day trading, an increase of 110% from the average session volume of 8,831 shares. The stock had previously closed at $1.32.
PharmaCyte Biotech Stock Performance
The company’s 50 day moving average is $1.60 and its 200 day moving average is $1.68.
PharmaCyte Biotech Company Profile
PharmaCyte Biotech, Inc is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes.
Read More
- Five stocks we like better than PharmaCyte Biotech
- What Does a Stock Split Mean?
- Conagra Stock Could Thrive as Tariffs Hit Other Sectors
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Grocery Costs and Tariffs Now Top of Mind in Everyday Conversations, New Survey Finds
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy?
Receive News & Ratings for PharmaCyte Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharmaCyte Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
